DeepMed Research

Amgen, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1980-01-01

Employees: 26.7K

Market Cap: $175.6B

Website: http://www.amgen.com

Clinical Trials

A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers

Phase 2

Terminated

Conditions: Relapsed or Refractory Multiple Myeloma

Interventions: Drug: Dexamethasone
Drug: Carfilzomib

First Posted Date: 2018-04-30

Last Posted Date: 2021-01-08

Lead Sponsor: Amgen

Target Recruit Count: 7

Registration Number: NCT03512353

Locations: 🇺🇸
Research Site, Yakima, Washington, United States

AMG 334 20160172 Pediatric Migraine PK Study.

Phase 1

Completed

Conditions: Migraine

Interventions: Drug: AMG 334 Dose 1
Drug: AMG 334 Dose 3
Drug: AMG 334 Dose 2

First Posted Date: 2018-04-17

Last Posted Date: 2024-05-28

Lead Sponsor: Amgen

Target Recruit Count: 53

Registration Number: NCT03499119

Locations: 🇺🇸
Arkansas Childrens Hospital, Little Rock, Arkansas, United States
🇺🇸
CarePoint, Englewood, Colorado, United States
🇺🇸
New England Institute for Clinical Research, Stamford, Connecticut, United States

and more 11 locations

Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

Phase 3

Completed

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Blinatumomab
Drug: Dexamthasone

First Posted Date: 2018-03-26

Last Posted Date: 2023-02-08

Lead Sponsor: Amgen

Target Recruit Count: 121

Registration Number: NCT03476239

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China

and more 20 locations

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia
AML
NHL
Myelodysplastic Syndrome
Multiple Myeloma
MDS
Non-Hodgkins Lymphoma

Interventions: Drug: AMG 397
Drug: Azacitidine
Drug: Dexamethasone

First Posted Date: 2018-03-14

Last Posted Date: 2023-04-12

Lead Sponsor: Amgen

Target Recruit Count: 24

Registration Number: NCT03465540

Locations: 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇫🇷
Institut Gustave Roussy, Villejuif, France
🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States

and more 18 locations

Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study

Phase 3

Completed

Conditions: Thyroid Eye Disease

Interventions: Biological: Teprotumumab

First Posted Date: 2018-03-09

Last Posted Date: 2024-06-28

Lead Sponsor: Amgen

Target Recruit Count: 51

Registration Number: NCT03461211

Locations: 🇺🇸
Hamilton Eye Institute at University of Tennessee Health, Memphis, Tennessee, United States
🇮🇹
University of Pisa, Department of Clinical and Experimental Medicine, Pisa, Italy
🇺🇸
Macro, Llc, Beverly Hills, California, United States

and more 10 locations

A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.

Phase 4

Completed

Conditions: Heart Failure (HF)

Interventions: Drug: Ivabradine

First Posted Date: 2018-03-07

Last Posted Date: 2021-10-28

Lead Sponsor: Amgen

Target Recruit Count: 30

Registration Number: NCT03456856

Locations: 🇺🇸
Research Site, Buffalo, New York, United States

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus

Phase 1

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Placebo
Drug: Efavaleukin Alfa

First Posted Date: 2018-03-01

Last Posted Date: 2023-07-19

Lead Sponsor: Amgen

Target Recruit Count: 35

Registration Number: NCT03451422

Locations: 🇺🇸
Metroplex Clinical Research Center, Dallas, Texas, United States
🇺🇸
Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
🇵🇱
Clinical Research Center Spzoo Medic-R Spolka Komandytowa, Poznan, Poland

and more 12 locations

AMG 714 Expanded Access Program

Conditions: Celiac Disease

First Posted Date: 2018-02-20

Last Posted Date: 2025-05-04

Lead Sponsor: Amgen

Registration Number: NCT03439475

Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia

Phase 3

Terminated

Conditions: Primary Hypercholesterolemia
Mixed Dyslipidemia

Interventions: Drug: placebo
Drug: evolocumab

First Posted Date: 2018-02-15

Last Posted Date: 2023-03-27

Lead Sponsor: Amgen

Target Recruit Count: 259

Registration Number: NCT03433755

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳
Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China

and more 28 locations

A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis

Phase 3

Completed

Conditions: Post-Menopausal Osteoporosis

Interventions: Device: romosozumab self-administration with AI/Pen
Drug: romosozumab HCP administration with PFS

First Posted Date: 2018-02-14

Last Posted Date: 2020-11-23

Lead Sponsor: Amgen

Target Recruit Count: 283

Registration Number: NCT03432533

Locations: 🇬🇧
Research Site, Romford, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy